Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.976
-0.054 (-5.24%)
At close: Nov 20, 2024, 4:00 PM
0.980
+0.004 (0.42%)
Pre-market: Nov 21, 2024, 7:01 AM EST
Enlivex Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 5 | 6.14 | 7.1 | 6.41 | 3.7 | 3.02 | |
| Research & Development | 13.66 | 19.01 | 18.69 | 12.88 | 6.09 | 5.6 | |
| Operating Expenses | 18.66 | 25.15 | 25.8 | 19.29 | 9.79 | 8.62 | |
| Operating Income | -18.66 | -25.15 | -25.8 | -19.29 | -9.79 | -8.62 | |
| Interest & Investment Income | 1.22 | 1.57 | 0.84 | 0.12 | 0.23 | 0.24 | |
| Currency Exchange Gain (Loss) | -0.41 | -1.22 | -4.1 | -0.56 | -2.26 | -0.95 | |
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.33 | -0.01 | -0.06 | |
| EBT Excluding Unusual Items | -17.85 | -24.82 | -29.08 | -20.06 | -11.82 | -9.38 | |
| Gain (Loss) on Sale of Investments | - | - | -1.98 | 5.59 | - | - | |
| Gain (Loss) on Sale of Assets | -4.45 | -4.24 | - | - | - | - | |
| Pretax Income | -22.29 | -29.07 | -31.06 | -14.47 | -11.82 | -9.38 | |
| Net Income | -22.29 | -29.07 | -31.06 | -14.47 | -11.82 | -9.38 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.2 | |
| Net Income to Common | -22.29 | -29.07 | -31.06 | -14.47 | -11.82 | -9.58 | |
| Shares Outstanding (Basic) | 19 | 19 | 18 | 18 | 13 | 9 | |
| Shares Outstanding (Diluted) | 19 | 19 | 18 | 18 | 13 | 9 | |
| Shares Change (YoY) | 2.08% | 0.98% | 3.00% | 35.62% | 52.25% | 146.47% | |
| EPS (Basic) | -1.18 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | |
| EPS (Diluted) | -1.18 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | |
| Free Cash Flow | -17.12 | -23.76 | -32.08 | -19.17 | -12.03 | -7.23 | |
| Free Cash Flow Per Share | -0.91 | -1.28 | -1.74 | -1.07 | -0.91 | -0.84 | |
| EBITDA | -17.89 | -24.32 | -25.02 | -18.74 | -9.5 | -8.41 | |
| D&A For EBITDA | 0.76 | 0.84 | 0.78 | 0.55 | 0.29 | 0.21 | |
| EBIT | -18.66 | -25.15 | -25.8 | -19.29 | -9.79 | -8.62 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.